Skip to main content

Agile Therapeutics Value Stock - Dividend - Research Selection

Agile therapeutics

ISIN: US00847L1008 , WKN: A1135H

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Agile Therapeutics, Inc., a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024

2023-11-22
PRINCETON, NJ / ACCESSWIRE / November 22, 2023 / Agile Therapeutics, Inc. (NASDAQ:AGRX), the commercial-stage women's healthcare company, posted a 122% increase in third-quarter revenue year-over-year, driven by strong demand for TwirlaⓇ (levonorgestrel ...

Agile Therapeutics reports Q3 results

2023-11-22
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Analysts Are Bullish on Top Healthcare Stocks: Mainz Biomed B.V. (MYNZ), Agile Therapeutics (AGRX)

2023-11-21
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Q3 2023 Earnings Call Transcript

2023-11-10
Agile Therapeutics, Inc. (NASDAQ:AGRX) Q3 2023 Earnings Call Transcript November 9, 2023 Agile Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-1.58. Operator: Good morning, and welcome to the Agile Therapeutics Third Quarter 2023 Financial Results Conference Call. Please note, today’s event is being recorded. I would now like to turn the […]

Agile Therapeutics: A Promising Investment with Positive Cash Flow Forecasts and Anticipated Growth in Twirla Sales

2023-11-10
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Agile Therapeutics, Inc. (AGRX) Q3 2023 Earnings Call Transcript

2023-11-09
Agile Therapeutics, Inc. (NASDAQ:NASDAQ:AGRX) Q3 2023 Earnings Call November 9, 2023 8:30 AM ETCompany ParticipantsMatt Riley - Head of Investor...

Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

2023-11-09
Twirla Delivers Third Quarter 2023 Net Revenue of $6.7 Million, a 21% Increase from Second Quarter 2023 Company Announces It Expects to Generate Positive Cash Flow from Operations in First Quarter 2024 Gross Margin Grows to 63% in Third Quarter 2023 from 58% in Second Quarter 2023 Company Reaffirms Expected Full Year 2023 Net Revenue of At Least $25 Million Management to Host Conference Call Today, Thursday, November 9, 2023 at 8:30 a.m. ET PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Agil

Agile Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation

2023-11-09
The following slide deck was published by Agile Therapeutics, Inc.

Agile Therapeutics: Q3 Earnings Snapshot

2023-11-09
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Agile Therapeutics reports Q3 EPS ($1.47) vs ($3.10) last year

2023-11-09
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.